STOCK TITAN

Medtronic plc - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic plc news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.

Medtronic plc (NYSE: MDT) is an American medical device company with its operational and executive headquarters in Minneapolis, Minnesota, and legal headquarters in Dublin, Ireland, following its acquisition of Covidien in 2015. As one of the largest medical-device companies globally, Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases.

The company’s extensive product portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. It markets these products to healthcare institutions and physicians worldwide, with international sales accounting for approximately 50% of its total revenue.

In a recent announcement on April 10, 2024, Medtronic unveiled significant advancements in artificial intelligence (AI) for endoscopic care through the launch of ColonPRO™ software for the GI Genius™ intelligent endoscopy system. This new software improves polyp detection and introduces procedural highlights to enhance physicians' workflow. The company has also entered into a collaboration with Modernizing Medicine® to integrate AI-driven data with electronic health records (EHR).

Medtronic recently reported its financial results for the fourth quarter and fiscal year 2024, showcasing a global revenue of $32.364 billion, a 3.6% increase compared to the previous year. The company's revenue growth was fueled by advancements in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

In addition to its financial performance, Medtronic has made strides in technological innovation. The U.S. FDA approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for chronic pain treatment, demonstrating the company’s commitment to addressing unmet clinical needs and improving patient care through advanced technologies.

Medtronic remains dedicated to its mission of alleviating pain, restoring health, and extending life, driven by a global team of over 95,000 employees across 150 countries. The company continues to leverage its diverse knowledge and insatiable curiosity to deliver innovative solutions that transform lives. For more information, visit Medtronic's official website.

Rhea-AI Summary
Medtronic plc (NYSE: MDT) expands partnership with Cosmo Pharmaceuticals to revolutionize endoscopy with cutting-edge AI technology. The agreement includes a $100 million upfront payment, double-digit royalties on net sales, and potential milestone payments of $100 million by 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
AI
-
Rhea-AI Summary
Medtronic plc (NYSE:MDT) approved a cash dividend of $0.69 per ordinary share for the third quarter of fiscal year 2024. The company has consistently increased its annual dividend payment for the past 46 years and is a constituent of the S&P 500 Dividend Aristocrats index. The dividend is payable on January 12, 2024, to shareholders of record at the close of business on December 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
dividends earnings
-
Rhea-AI Summary
Medtronic (MDT) focuses on reducing health disparities in a meaningful, sustainable, and scalable way
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
Rhea-AI Summary
Medtronic LABS (MDT) makes its digital health platform SPICE open source, accelerating access to healthcare in underserved communities. Since 2013, the nonprofit has enrolled over 217,000 people in one million patients healthcare and trained over 8,000 community health workers in multiple countries. SPICE is a digital health platform embedded within health systems and government digital ecosystems, screening patients for various conditions and connecting them to care. Becoming open source allowed LABS to receive the designation as a Digital Public Good by a United Nations-endorsed initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary
Medtronic plc (MDT) reported a 5.3% revenue growth in Q2 of fiscal year 2024, reaching $8.0 billion. The company raised its fiscal year guidance for organic revenue growth and EPS. They received U.S. FDA approval for innovative products and witnessed strong performance across multiple businesses and geographies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.6%
Tags
-
Rhea-AI Summary
Medtronic plc (NYSE: MDT) - FDA Approves Symplicity Blood Pressure Procedure, Offering Patients a New Adjunct Approach to Lowering Blood Pressure - Medtronic's Symplicity blood pressure procedure, also known as the Symplicity Spyral renal denervation (RDN) system, has been approved by the FDA for the treatment of hypertension. This approval marks a significant milestone in the treatment of high blood pressure, providing a minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys to help manage blood pressure. The procedure has been shown to be safe and effective, offering significant blood pressure reductions for patients. Medtronic will immediately begin commercialization of the Symplicity blood pressure procedure, aiming to fulfill the significant unmet need in hypertension care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
Rhea-AI Summary
Medtronic - Survey Reveals Optimism for AI in Healthcare
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
AI
-
Rhea-AI Summary
Medtronic: Survey Reveals Optimism for AI in Healthcare
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
AI
-
News
Rhea-AI Summary
Medtronic (MDT) collaborates with the Ministry of Health, Royal Government of Bhutan, ADA, The United Nations Technology Bank, MED-EL, and others to revolutionize pediatric ear and hearing care in Bhutan. The World Health Organization (WHO) reports 32 million children worldwide affected by hearing loss, with 60% preventable through early detection and public health measures. In Bhutan, 2.2% of the population has some form of hearing disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Rhea-AI Summary
Medtronic plc (NYSE: MDT) will report financial results for its second quarter of fiscal year 2024 on November 21, 2023. The news release will include summary financial information for the company's second quarter, which ended on October 27, 2023. A video webcast to discuss the results will be hosted at 7:00 a.m. CST on November 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags

FAQ

What is the current stock price of Medtronic plc (MDT)?

The current stock price of Medtronic plc (MDT) is $86.21 as of November 22, 2024.

What is the market cap of Medtronic plc (MDT)?

The market cap of Medtronic plc (MDT) is approximately 109.1B.

What does Medtronic plc specialize in?

Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools.

Where are Medtronic’s headquarters located?

Medtronic’s operational and executive headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Dublin, Ireland, following its acquisition of Covidien in 2015.

How significant are Medtronic’s international sales?

International sales account for roughly 50% of Medtronic’s total revenue.

What recent advancements has Medtronic made in AI for healthcare?

Medtronic recently launched the ColonPRO™ software for the GI Genius™ intelligent endoscopy system, enhancing AI-driven polyp detection and procedural highlights. The company also partnered with Modernizing Medicine® to integrate AI data with EHR systems.

What are Medtronic’s recent financial achievements?

Medtronic reported a global revenue of $32.364 billion for fiscal year 2024, a 3.6% increase from the previous year, driven by growth in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

What new technology has Medtronic introduced for chronic pain treatment?

Medtronic introduced the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS), which the U.S. FDA approved for the treatment of chronic pain.

How many employees does Medtronic have worldwide?

Medtronic has a global team of over 95,000 employees across 150 countries.

What is Medtronic’s mission?

Medtronic's mission is to alleviate pain, restore health, and extend life.

Where can I find more information about Medtronic?

For more information about Medtronic, visit their official website at Medtronic.com.

How does Medtronic approach innovation in healthcare?

Medtronic leverages its diverse knowledge, insatiable curiosity, and commitment to helping those in need to deliver innovative technologies that transform lives, focusing on engineering extraordinary healthcare solutions.

Medtronic plc

NYSE:MDT

MDT Rankings

MDT Stock Data

109.06B
1.28B
0.26%
85.42%
0.79%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GALWAY